Xlife Sciences Forecast, price target & analysts
Xlife Sciences Target price 2025 - Analyst rating & recommendation
Xlife Sciences Classifications & Recommendation:
Xlife Sciences Price Target
| Target Price | CHF69.36 |
| Price | CHF19.75 |
| Potential |
251.19%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Xlife Sciences 2026 .
The average Xlife Sciences target price is CHF69.36.
This is
251.19%
register free of charge
CHF71.40
261.52%
register free of charge
CHF68.68
247.75%
register free of charge
|
|
| A rating was issued by 5 analysts: 4 Analysts recommend Xlife Sciences to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Xlife Sciences stock has an average upside potential 2026 of
251.19%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 0.83 | 2.15 |
| 16.16% | 158.43% | |
| EBITDA Margin | -400.00% | -322.49% |
| 6.60% | 19.38% | |
| Net Margin | 4,130.12% | -173.52% |
| 174.79% | 104.20% |
2 Analysts have issued a sales forecast Xlife Sciences 2025 . The average Xlife Sciences sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF830k | 16.16% |
|---|---|---|
| 2025 |
CHF2.1m
158.43%
Unlock
|
|
2 Analysts have issued an Xlife Sciences EBITDA forecast 2025. The average Xlife Sciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF-3.3m | 21.70% |
|---|---|---|
| 2025 |
CHF-6.9m
108.36%
Unlock
|
|
EBITDA Margin
| 2024 | -400.00% | 6.60% |
|---|---|---|
| 2025 |
-322.49%
19.38%
Unlock
|
|
2 Xlife Sciences Analysts have issued a net profit forecast 2025. The average Xlife Sciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF34.3m | 130.38% |
|---|---|---|
| 2025 |
CHF-3.7m
110.85%
Unlock
|
|
Net Margin
| 2024 | 4,130.12% | 174.79% |
|---|---|---|
| 2025 |
-173.52%
104.20%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 4.67 | -0.65 |
| 124.52% | 113.92% | |
| P/E | negative | |
| EV/Sales | 79.54 |
2 Analysts have issued a Xlife Sciences forecast for earnings per share. The average Xlife Sciences EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF4.67 | 124.52% |
|---|---|---|
| 2025 |
CHF-0.65
113.92%
Unlock
|
|
P/E ratio
| Current | 4.23 | 77.13% |
|---|---|---|
| 2025 |
-30.46
820.25%
Unlock
|
|
Based on analysts' sales estimates for 2025, the Xlife Sciences stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 205.55 | 12.12% |
|---|---|---|
| 2025 |
79.54
61.30%
Unlock
|
|
P/S ratio
| Current | 134.21 | 24.12% |
|---|---|---|
| 2025 |
51.93
61.31%
Unlock
|
|
Current Xlife Sciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ALPHAVALUE |
Locked
➜
Locked
|
Locked | Sep 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
ALPHAVALUE:
Locked
➜
Locked
|
Sep 04 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
